用于治疗帕金森病患者胃肠道症状的理气剂疗效与安全性的开放标签试验:一项初步研究

Open Label Trial of the Efficacy and Safety Profile of Rikkunshito used for the Treatment of Gastrointestinal Symptoms in Patients with Parkinson's Disease: A Pilot Study.

作者信息

Yakabi Koji, Yamaguchi Naomi, Ono Shino, Yoshida Norihito, Hosomi Eriko, Hayashi Kenjiro, Ochiai Mitsuko, Maezawa Kosuke, Nomura Kyoichi

机构信息

Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Department of Gastroenterology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

出版信息

Curr Ther Res Clin Exp. 2017 Jul 31;87:1-8. doi: 10.1016/j.curtheres.2017.07.003. eCollection 2017.

Abstract

BACKGROUND

Patients with Parkinson's disease (PD) usually experience distress related not only to motor dysfunction, but also to nonmotor symptoms, including gastrointestinal dysfunction.

OBJECTIVE

The purpose of this pilot study was to evaluate the efficacy and safety profile of a traditional Japanese medicine, rikkunshito (RKT), used for the treatment of gastrointestinal symptoms, associated with anorexia and dyspepsia, in patients with PD.

METHODS

Patients were randomly assigned to either Group A (4-week treatment period with 7.5 g/d RKT followed by a 4-week off-treatment period) or Group B (4-week off-treatment period followed by a 4-week treatment period with 7.5 g/d RKT). Appetite, quality of life for gastrointestinal symptoms, and depression were assessed using a visual analog scale, the Gastrointestinal Symptom Rating Scale and the Self-Rating Depression Scale, respectively. The gastric emptying examination and assay of plasma acylated ghrelin level were performed using the C-acetate breath test and commercially available assay kits, respectively.

RESULTS

RKT treatment produced a significant increase in the appetite score (1.84 [2.34]; < 0.05), compared to a decrease in the score over the off-treatment period (-1.36 [2.94]). The mean score for abdominal pain, on the Gastrointestinal Symptom Rating Scale, and for self-reported depression, on the Self-Rating Depression Scale, also decreased significantly with RKT treatment ( < 0.05), compared with the off-treatment period scores. No effect of RKT on plasma acylated ghrelin level and rate of gastric emptying was identified.

CONCLUSIONS

RKT may improve anorexia in patients with PD. The positive effects of RKT on depression and anorexia may improve the overall quality of life of these patients. The benefits of RKT identified in our pilot study will need to be confirmed in a randomized, double-blind, controlled trial. UMIN Clinical Trial Registry identifier: UMIN000009626.

摘要

背景

帕金森病(PD)患者通常不仅会因运动功能障碍而感到痛苦,还会因非运动症状(包括胃肠功能障碍)而痛苦。

目的

本初步研究旨在评估一种用于治疗PD患者胃肠症状(伴有厌食和消化不良)的传统日本药物——理气剂(RKT)的疗效和安全性。

方法

患者被随机分为A组(接受为期4周、每日7.5克RKT的治疗,随后为4周的停药期)或B组(先进行4周的停药期,随后接受为期4周、每日7.5克RKT的治疗)。分别使用视觉模拟量表、胃肠症状评分量表和自评抑郁量表评估食欲、胃肠症状的生活质量和抑郁情况。分别使用C-醋酸呼气试验和市售检测试剂盒进行胃排空检查和血浆酰化胃泌素水平检测。

结果

与停药期评分下降(-1.36[2.94])相比,RKT治疗使食欲评分显著增加(1.84[2.34];P<0.05)。与停药期评分相比,RKT治疗后胃肠症状评分量表上的腹痛平均评分以及自评抑郁量表上自我报告的抑郁评分也显著降低(P<0.05)。未发现RKT对血浆酰化胃泌素水平和胃排空率有影响。

结论

RKT可能改善PD患者的厌食症状。RKT对抑郁和厌食的积极作用可能会改善这些患者的整体生活质量。我们初步研究中发现的RKT的益处需要在随机、双盲、对照试验中得到证实。UMIN临床试验注册标识符:UMIN000009626。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a385/5583142/f44e2cd80048/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索